Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor in atopic dermatitis

7 hours ago
1 min read

He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.

Recent Posts

See All

From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it

From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication

From London: Resolution Therapeutics is in the clinic with its engineered regenerative macrophage therapy to treat end stage liver disease

Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor in atopic dermatitis

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight